• Cardioprotection by SGLT2 Inhibitors: Is It a Class or Drug

  2026-07-01

  This study investigates whether cardioprotective effects observed with SGLT2 inhibitors are consistent across different drugs or attributable to individual agents. Using a non-diabetic mouse model of myocardial ischemia/reperfusion injury, the research demonstrates that empagliflozin and dapagliflozin reduce infarct size at standard doses, whereas ertugliflozin only does so at higher dosing. The findings highlight crucial mechanistic differences within the SGLT2 inhibitor class, informing future translational research.

• FGFR3 Inhibition with NVP-BGJ398 Ameliorates SLC26A2 Chondro

  2026-06-30

  This study uncovers that pharmacological inhibition of FGFR3 signaling, particularly via NVP-BGJ398 phosphate, significantly ameliorates skeletal defects in mouse models of SLC26A2-related chondrodysplasia. These findings provide rigorous genetic and pharmacological evidence for targeting the FGFR pathway in rare skeletal dysplasias, informing future translational and therapeutic directions.

• GSK343: Advancing EZH2 Inhibitor Assays for Epigenetic Cance

  2026-06-30

  Explore how GSK343, a potent EZH2 inhibitor, transforms cancer epigenetics research by enabling precise histone H3K27 trimethylation inhibition. This article uniquely bridges chromatin regulation, TERT expression, and practical assay optimization.

• Distinct Cell Death Pathways in ALL Cells After Microtubule

  2026-06-29

  This study reveals that primary acute lymphoblastic leukemia (ALL) cells undergo phase-specific cell death upon microtubule depolymerization, with apoptosis in M phase and a caspase-independent pathway in G1. These findings refine our understanding of microtubule targeting agent (MTA) mechanisms and have implications for optimizing cancer therapies targeting both mitotic and interphase cancer cell populations.

• Dorsomorphin 2HCl: AMPK Inhibitor Workflows in Metabolic Res

  2026-06-29

  Dorsomorphin 2HCl, a benchmark AMPK inhibitor, is central to dissecting metabolic and bone morphogenetic pathways with high specificity in preclinical models. This guide details optimized workflows, troubleshooting tips, and key translational insights—bridging protocol nuance with real-world use-cases in iron homeostasis and hepatic lipid research.

• Elobixibat Hydrate: Mechanistic Insights and Protocol Advanc

  2026-06-28

  Explore the in-depth mechanism of Elobixibat hydrate, a leading ileal bile acid transporter inhibitor, and learn how its unique pharmacology can refine research protocols in metabolic and gastrointestinal studies. Uncover scientific distinctions and practical assay guidance beyond standard product reviews.

• 1-myristoylglycerophosphocholine: Applied Lipid Signaling in

  2026-06-27

  1-myristoylglycerophosphocholine (14:0 Lyso-PC) is redefining how researchers interrogate lipid signaling in smooth muscle and pulmonary fibrosis models. This guide demystifies experimental design, troubleshooting, and advanced applications, translating new mechanistic insights into actionable protocols for lipid pathway analysis.

• Pterostilbene Enhances Mitochondrial Quality to Delay Dermal

  2026-06-26

  Zhou et al. (2025) demonstrate that pterostilbene mitigates senescence in human dermal fibroblasts by improving mitochondrial quality, principally through enhanced mitophagy. These findings clarify mechanisms underlying dermal aging and suggest mitochondrial quality control as a promising intervention target.

• EZ Cap Cy5 Firefly Luciferase mRNA: Precision Tracking and T

  2026-06-26

  Explore how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) revolutionizes mRNA delivery tracking and translation efficiency. This in-depth analysis reveals unique dual-mode imaging capabilities and bridges new evidence on tissue-specific mRNA translation.

• Selective SGLT2 Inhibitors and Cardioprotection: Insights fr

  2026-06-25

  This study systematically investigated the cardioprotective effects of selective SGLT2 inhibitors—including Ertugliflozin—in a non-diabetic mouse model of myocardial ischemia/reperfusion injury. The findings clarify drug-specific differences in infarct size reduction, reveal that cardioprotection is not an inherent class effect at standard dosing, and highlight the mechanistic independence from glucose reabsorption inhibition.

• Penicillin G Sodium: Reliable Solutions for Cell-Based Assay

  2026-06-25

  This article provides evidence-based guidance for biomedical researchers and lab technicians on the use of Penicillin G Sodium (SKU B1678) to ensure reproducibility and contamination control in cell viability, proliferation, and cytotoxicity workflows. Drawing on real laboratory scenarios, the discussion highlights APExBIO's Penicillin G Sodium as a high-purity, workflow-compatible natural penicillin antibiotic.

• Dorsomorphin (Compound C): Selective AMPK & BMP Pathway Inhi

  2026-06-24

  Dorsomorphin (Compound C) is a potent, reversible ATP-competitive inhibitor of AMP-activated protein kinase (AMPK) with high selectivity and dual action on BMP signaling. It is widely used to dissect metabolic, autophagic, and differentiation pathways at the bench. The compound’s specificity and robust action profile enable reproducible, mechanistic studies in cellular and animal models.

• Elobixibat Hydrate: Applied Workflows for GI and Metabolic R

  2026-06-23

  Elobixibat hydrate, a highly selective ileal bile acid transporter inhibitor, is reshaping experimental approaches in gastrointestinal and metabolic research. This article translates mechanistic insights and protocol guidelines into actionable workflows for chronic constipation, colonoscopy prep, and metabolic studies—enabling reproducibility and innovation at the bench.

• Wortmannin as a PI3K Inhibitor: Workflows, Use-Cases & Tips

  2026-06-23

  Wortmannin’s nanomolar potency and selectivity for PI3K make it indispensable for dissecting complex cell signaling, autophagy, and viral entry. This article synthesizes experimental best practices, cross-domain insights, and troubleshooting strategies to maximize research outcomes with Wortmannin.

• Ertugliflozin (PF-04971729): SGLT2 Inhibitor for Diabetes Re

  2026-06-22

  Ertugliflozin (PF-04971729) is a highly selective SGLT2 inhibitor with proven efficacy in reducing renal glucose reabsorption and lowering glycated hemoglobin in type 2 diabetes research models. The compound demonstrates over 2000-fold selectivity for SGLT2 versus SGLT1 and offers cardiovascular and renal protection. APExBIO supplies Ertugliflozin A3715 with verified purity and stability for experimental workflows.

454 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page